📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors https://t.co/Tdqxk72OGi
@MathieuSpaas@JAMAOnc Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit.
https://t.co/hAZBi2LawL
If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.
@gv_lazcano@JAMAOnc Similar to PEMBRO-RT and @seanmmcbride we hypothesized that higher SBRT doses might abrogate a potential immune stimulatory effect, based on preclinical data by @CVanpouilleBox
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors https://t.co/Tdqxk72OGi
✅Conclusion: while safe, adding subablative multisite SBRT to anti-PD-(L)1 monotherapy did not result in a clinically meaningful benefit
🙏 Thank you to pts, families, trial staff and investigators for participating in this @komop_tgkanker and @VarianMedSys sponsored trial!
👥 >2/3 polyM+ pts and >1st line systemic Tx
😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness
☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes
This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020
➡️ Randomized 1:1 between 💉anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions
Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! #RTimmuno#checkpoint blockade #precisionRT @ASTRO_org https://t.co/PuSN6yJMEK
Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet#OncoAlert